ASXL1 and cancer: The loss of PRC2 repression in ASXL1 mutant cell lines has been functionally demonstrated in cancer cell lines32, as well as in human CD34+ cells following ASXL1 knockdown33, and it is compelling to observe this mechanism in primary patient samples.